Teva Faces 463-Million-Euro Fine from EU for Antitrust Violations
Thursday, 31 October 2024, 12:52
Teva's Antitrust Violations
The EU has imposed a 463-million-euro fine on Teva, the world's largest generic drugmaker, for abusing its dominant market position.
Details of the Fine
- Amount: 463 million euros (approximately $502 million)
- Reason: Impeding competition surrounding a blockbuster drug
- Date of announcement: Thursday
Impact on the Pharmaceutical Industry
This significant fine is a reminder of the EU's commitment to maintain fair competition and protect market integrity within the healthcare sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.